Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 October 2024 | Story Precious Shamase | Photo Supplied
Sibahle Mabaso
Sibahle Mabaso during her BA (Hons) Drama and Theatre Arts (2022) graduation, which she passed cum laude.

Sibahle Mabaso, a talented and driven individual, has been making waves at the University of the Free State (UFS). As a runner-up in the prestigious Siyaphumelela ATD DREAM Scholar programme, Mabaso's dedication and achievements have not gone unnoticed.

A multi-faceted student, Mabaso excelled in both her academic pursuits and extracurricular activities. A graduate of the UFS Drama and Theatre Arts programme, Mabaso's academic pursuits have been as diverse as her interests. She has a BA in Drama and Theatre Arts (2019-2021), a BA Honours in Drama and Theatre Arts (2022), and she is currently pursuing a Master of Arts with specialisation in Gender Studies.  Her passion for the arts is evident in her work as a playwright, director, and educator. Mabaso is currently an Assistant Researcher in Transition, Development and Success within the Centre for Teaching and Learning.

Mabaso's journey to academic success has been marked by resilience and perseverance. Despite facing challenges, she has overcome obstacles through hard work, determination, and the support of mentors.

Beyond her academic achievements, Mabaso is committed to giving back to her community. She recently founded a creative enterprise called Wild Geese PTY LTD, which aims to provide opportunities for young creatives. Through her work, Mabaso hopes to inspire and mentor others, sharing her experiences and knowledge to help them reach their full potential.

As Mabaso continues her academic journey and pursues her career goals, her dedication and passion for both her studies and community engagement are sure to inspire others. Her achievements serve as a testament to the power of hard work, resilience, and a commitment to making a positive impact. Looking ahead, Mabaso hopes to continue her academic pursuits and pursue a career in higher education. She is also passionate about giving back to her community and mentoring young people. With her talent, dedication, and unwavering spirit, there is no doubt that Sibahle Mabaso will continue to achieve great things.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept